Zydus Cadila's Covid vaccine will be rolled out soon: V K Paul
'We will take a final decision based on the overall scientific rationale and the supply situation of the child licenced vaccines, going forward,' says Covid Task Force chief17-10-2021
17-10-2021
Vaccines for malaria and dengue may hit Indian market in 2-4 years
There are several candidates in the works - the Serum Institute of India, Bharat Biotech, and Zydus Cadila are working on either developing or manufacturing anti-malarial vaccines12-10-2021
Cadila Healthcare Ltd - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Loss of share certificate11-10-2021
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Fortress Biotech and Cyprium Therapeutics with support from its licensing partner Sentynl Therapeutics, Inc. a wholly owned subsidiary of Cadila Healthcare Limited ('Zydus') Announce Positive Clinical Data for CUTX-101, Copper Histidinate for the treatment of Menkes Disease08-10-2021
Zydus Cadila gets tentative nod from USFDA to market generic acne drug
Drug firm Zydus Cadila on Friday said it has received tentative nod from the US health regulator to market generic Adapalene and Benzoyl Peroxide gel used for treatment of acne in the American market. The company has received tentative approval from the United States Food and Drug Administration (USFDA) to market Adapalene and Benzoyl Peroxide Gel 0.3 per cent/2.5 per cent, Zydus Cadila said in a statement. The drug will be manufactured at the group's topical plant at Ahmedabad, it added. Adapalene and Benzoyl Peroxide combination is used to treat acne. It works by killing the bacteria that cause acne and by keeping the skin pores clean, Zydus Cadila said. The group now has 323 approvals and has so far filed over 400 abbreviated new drug applications (ANDAs) since the commencement of its filing process, it added. Shares of Cadila Healthcare, the listed entity of the group, were trading at Rs 550.55 per scrip on BSE, up 0.18 per cent from their previous close.08-10-2021
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release dated 08/10/202108-10-2021
CADILA HEALTHCARE LTD. - 532321 - Statement Of Investor Complaints For The Quarter Ended September 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 1120 Name of the Signatory :- Dhaval N SoniDesignation :- Company Secretary and Compliance Officer07-10-2021
CADILA HEALTHCARE LTD. - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Loss of share certificate07-10-2021
Cadila Healthcare Q2 PAT seen up 19% YoY to Rs 563.3 cr: Prabhudas Lilladher
Net Sales are expected to decrease by 3.5 percent Y-o-Y (down 8.4 percent Q-o-Q) to Rs 3,685.8 crore, according to Prabhudas Lilladher.06-10-2021
Cadila Healthcare Ltd - 532321 - Shareholding for the Period Ended September 30, 2021
Cadila Healthcare Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2021. For more details, kindly Click here06-10-2021